Irritable Bowel Syndrome – Epidemiology – Emerging Markets

Clarivate Epidemiology’s coverage of irritable bowel syndrome comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report prevalence of irritable bowel syndrome for each country, as well as annualized case counts projected to the national population.

Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s irritable bowel syndrome forecast will answer the following question:

• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of irritable bowel syndrome over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts five irritable bowel syndrome patient populations, as follows:

• Total prevalent cases
• Irritable bowel syndrome with predominant constipation (IBS-C) prevalent cases
• Irritable bowel syndrome with predominant diarrhea (IBS-D) prevalent cases 
• Irritable bowel syndrome with mixed bowel habits (IBS-M) prevalent cases
• Irritable bowel syndrome unclassified (IBS-U) prevalent cases

Note: Coverage may vary by country.